

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 October 2002 (24.10.2002)

PCT

(10) International Publication Number
WO 02/083891 A2

- (51) International Patent Classification⁷: **C12N 15/00**
- (21) International Application Number: **PCT/US02/11683**
- (22) International Filing Date: **12 April 2002 (12.04.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/283,618 **13 April 2001 (13.04.2001)** **US**
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US **60/283,618 (CIP)**
Filed on **13 April 2001 (13.04.2001)**
- (71) Applicant (for all designated States except US): **THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US];** West 116th Street and Broadway, New York, NY 10027 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **CHRISTIANO, Angela, M. [US/US];** 71 Burnett Terrace, West Orange, NJ 07052 (US).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/083891 A2

(54) Title: **NUCLEIC ACIDS FOR INHIBITING HAIRLESS PROTEIN EXPRESSION AND METHODS OF USE THEREOF**

(57) Abstract: The present invention provides DNazymes and ribozymes that specifically cleave Hairless Protein mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of Hairless Protein mRNA. The invention also provides various methods of inhibiting the expression of Hairless Protein. Finally the invention provides pharmaceutical compositions containing the instant DNazymes, ribozymes and antisense oligonucleotides as active ingredients.

NUCLEIC ACIDS FOR INHIBITING HAIRLESS PROTEIN
EXPRESSION AND METHODS OF USE THEREOF

5

This application is a continuation-in-part and claims the benefit of copending U.S. Provisional Application No. 60/283,618, filed April 13, 2001, the contents of which are hereby incorporated by reference.

10

Background of the Invention

The Hairless Gene

15 The hairless mouse, a frequent subject of different dermatological experiments, is characterized by hair loss that starts at the age of 14 days postpartum from the upper eyelids and progresses caudally. The process is completed by the age of 3 weeks, when the mice are
20 entirely naked and never grow hair again (Panteleyev et al. 1998b). The phenotype results from proviral integration and consequential aberrant splicing in the mouse hairless gene. Lack of expression of the mouse hairless gene due to inherited mutations leads to the
25 complete loss of hair, known as atrichia. Other mutations have been identified in other mouse hairless alleles, and its human equivalent, resulting in essentially similar phenotypes (Ahmad et al. 1998a; Ahmad et al. 1998b; Panteleyev et al. 1998a). Those studies demonstrated that
30 hairless expression in the hair follicle is necessary for hair cycling, specifically in the transition to the catagen phase.

35

Catalytic Nucleic Acid Molecules

Gene therapy is perhaps the most exciting promise of modern medical science. The technology of replacing mutant genes with correct ones can provide definitive therapy for a number of diseases. There are, however, conditions - inherited and acquired alike - which cannot be treated by the introduction of a new gene. In many cases, the ablation of an already existing gene may be desirable. In many dominantly inherited diseases, the successful "knock-out" of the mutant gene is, in theory, sufficient to cure the disease. In some other cases, the elimination of a normally functioning, wild-type gene may be necessary for therapeutic gene targeting.

Such is the case in abundant hair growth or hirsutism, in which inhibiting genes which promote hair growth could lead to decreased hair growth and, therefore, improvement. One way to achieve targeted, transient gene suppression is likely going to be through the use of catalytic nucleic acid technology, which includes both ribozymes and DNAzymes.

Ribozymes are RNA structures having a self-catalytic enzymatic function which, together with their sequence-specific and RNA-binding ability, make them capable of cleaving other RNA molecules at specific target sequences (Cech 1987). Recent success has been achieved in engineering ribozymes capable of selectively recognizing target sequences carrying different types of mutations, including single base-pair missense mutations (Parthasarathy et al. 1999; Sioud and Drlica 1991; Vaish et al. 1998).

These encouraging achievements give new perspective to

experimental strategies using selective mRNA ablation (Phylactou et al. 1998). The different groups of ribozymes described thus far (including hairpin ribozymes, hammerhead ribozymes and group I intron ribozymes (Bartel 1999)) have different characteristics with respect to their mechanism of splicing, splicing efficiency and target specificity. Several studies have used hammerhead ribozymes to selectively cleave RNA because of the superior target specificity of these ribozymes (Long and Sullenger 1999; Phylactou et al. 1998; Vaish et al. 1998).

Ribozymes can be delivered exogenously, such that the ribozymes are synthesized *in vitro*. They are usually administered using carrier molecules (Sioud 1996) or without carriers, using ribozymes specially modified to be nuclease-resistant (Flory et al. 1996). The other method is endogenous delivery, in which the ribozymes are inserted into a vector (usually a retroviral vector) which is then used to transfect target cells. There are several possible cassette constructs to choose from (Vaish et al. 1998), including the widely used U1 snRNA expression cassette, which proved to be efficient in nuclear expression of hammerhead ribozymes in various experiments (Bertrand et al. 1997; Michienzi et al. 1996; Montgomery and Dietz 1997).

Recent efforts have led to the successful development of small DNA oligonucleotides that have a structure similar to the hammerhead ribozyme (Santoro and Joyce 1997). These molecules are known as "deoxy-ribozymes", "deoxyribozymes" and "DNAzymes", and are virtually DNA equivalents of the hammerhead ribozymes. They consist of a 15 bp catalytic core and two sequence-specific arms with a typical length of 5-13 bp each (Santoro and Joyce

1998). Deoxy-ribozymes have more lenient consensus cleavage site requirements than hammerhead ribozymes, and are less likely to degrade when used for *in vivo* applications. The most widely used type of these novel
5 catalytic molecules is known as the "10-23" deoxy-ribozyme, whose designation originates from the numbering used by its developers (Santoro and Joyce 1997). Because of their considerable advantages, deoxy-ribozymes have already been used in a wide spectrum of *in vitro* and *in*
10 *vivo* applications (Cairns et al. 2000; Santiago et al. 1999).

Summary Of The Invention

This invention provides a catalytic deoxyribonucleic acid molecule that specifically cleaves Hairless Protein mRNA
5 comprising:

- (a) a catalytic domain that cleaves mRNA at a defined consensus sequence;
- (b) a binding domain contiguous with the 5' end of the catalytic domain; and
- 10 (c) a binding domain contiguous with the 3' end of the catalytic domain,

wherein the binding domains are complementary to, and therefore hybridize with, the two regions flanking the defined consensus sequence within the Hairless Protein
15 mRNA at which cleavage is desired, and wherein each binding domain is at least 4 residues in length, and both binding domains have a combined total length of at least 8 residues.

20 This invention also provides a catalytic ribonucleic acid molecule that specifically cleaves Hairless Protein mRNA comprising:

- (a) a catalytic domain that cleaves mRNA at a defined consensus sequence;
- 25 (b) a binding domain contiguous with the 5' end of the catalytic domain; and
- (c) a binding domain contiguous with the 3' end of the catalytic domain,

wherein the binding domains are complementary to, and
30 therefore hybridize with, the two regions flanking the defined consensus sequence within the Hairless Protein mRNA at which cleavage is desired, and wherein each binding domain is at least 4 residues in length, and both binding domains have a combined total length of at least
35 8 residues.

This invention also provides a first pharmaceutical composition comprising the instant catalytic ribonucleic acid molecule or deoxyribonucleic acid molecule and a pharmaceutically acceptable carrier.

5

This invention further provides a method of specifically cleaving Hairless Protein mRNA comprising contacting the mRNA with either of the instant catalytic nucleic acid molecules under conditions permitting the molecule to
10 cleave the mRNA.

This invention further provides a method of specifically cleaving Hairless Protein mRNA in a cell, comprising contacting the cell containing the mRNA with either of
15 the instant catalytic nucleic acid molecules so as to specifically cleave the hairless protein mRNA in the cell.

This invention further provides a method of specifically
20 inhibiting the expression of Hairless Protein in a cell that would otherwise express Hairless Protein, comprising contacting the cell with either of the instant catalytic nucleic acid molecules so as to specifically inhibit the expression of Hairless Protein in the cell.

25

This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising administering to the subject an amount of either of the instant catalytic nucleic acid
30 molecules effective to specifically inhibit the expression of Hairless Protein in the subject's cells.

This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a
35 subject's cells comprising administering to the subject

an amount of the first pharmaceutical composition effective to specifically inhibit the expression of Hairless Protein in the subject's cells.

- 5 This invention further provides a method of inhibiting hair production by a hair-producing cell comprising contacting the cell with an effective amount of either of the instant catalytic nucleic acid molecules.
- 10 This invention further provides a method of inhibiting hair growth in a subject comprising administering to the subject an effective amount of the first pharmaceutical composition.
- 15 This invention further provides a method of inhibiting the transition of a hair follicle from the anagen phase to the catagen phase comprising contacting the follicle with an effective amount of either of the instant catalytic nucleic acid molecules or the first
- 20 pharmaceutical composition.

This invention further provides a vector which comprises a sequence encoding either of the instant catalytic nucleic acid molecules.

- 25 This invention further provides a host-vector system comprising a cell having the instant vector therein. This invention still further provides a method of producing either of the instant catalytic nucleic acid molecules
- 30 comprising culturing a cell having therein a vector comprising a sequence encoding either catalytic nucleic acid molecule under conditions permitting the expression of the catalytic nucleic acid molecule by the cell.

- 35 This invention further provides a nucleic acid molecule

that specifically hybridizes to Hairless Protein mRNA so as to inhibit the translation thereof in a cell.

5 The invention further provides a second pharmaceutical composition comprising (a) the instant nucleic acid molecule or the instant vector and (b) a pharmaceutically acceptable carrier.

10 This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a cell that would otherwise express Hairless Protein, comprising contacting the cell with the instant nucleic acid molecule so as to specifically inhibit the expression of Hairless Protein in the cell.

15 This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising administering to the subject an amount of the instant nucleic acid molecule effective to specifically inhibit the expression of Hairless Protein in the subject's cells.

20 This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising administering to the subject an amount of the second pharmaceutical composition effective to specifically inhibit the expression of Hairless Protein in the subject's cells.

30 This invention further provides a method of inhibiting hair production by a hair-producing cell comprising contacting the cell with an effective amount of the instant nucleic acid molecule.

35 This invention further provides a method of inhibiting

hair growth in a subject comprising administering to the subject an effective amount of the second pharmaceutical composition.

- 5 This invention further provides a method of inhibiting the transition of a hair follicle from the anagen phase to the catagen phase comprising contacting the follicle with an effective amount of the instant nucleic acid molecule or the second pharmaceutical composition.

10

This invention further provides a method of producing the instant nucleic acid molecule comprising culturing a cell having therein a vector comprising a sequence encoding said nucleic acid molecule under conditions permitting
15 the expression of the nucleic acid molecule by the cell.

Finally this invention provides a non-human transgenic mammal, wherein the mammal's genome:

- (a) has stably integrated therein a nucleotide sequence
20 encoding a human Hairless Protein operably linked to a promoter, whereby the nucleotide sequence is expressed; and
(b) lacks an expressible endogenous hairless Protein-encoding nucleic acid sequence.

Brief Description of the Figures

Figures 1A - 1C: These figures show the mRNA sequence of Human Hairless Protein.

5

Figures 2A - 2D: Figures 2B - 2D show the pathology of C67BL/J mice treated with anti-Hairless Protein deoxyribozymes. Figure 2A shows a control area treated with a non-specific deoxyribozyme.

10

Figure 3: This figure shows reverse transcriptase polymerase chain reaction products visualized on an ethidium bromide-containing 2% agarose gel under UV light. Those deoxyribozymes that were capable of cleaving the target mouse Hairless Protein mRNA with the highest efficiency were used for *in vivo* experiments, as shown in lanes 1 ("702") and 3 ("754\sh").

Figure 4: This figure shows antisense oligonucleotide inhibition of Hairless Protein expression in Cos-1 cells. Lane 1 is the negative control where cells were not transfected with the full-length Hairless construct. Lane 2 shows Hairless expression in the positive control experiment where antisense oligonucleotides were not introduced. Lanes 3 and 4 show the inhibition of Hairless where anti-Hairless antisense ODN1 (SEQ ID NO:26) and ODN2 (SEQ ID NO:27), respectively, were added to the medium at 40 μ M concentration prior to transfection.

30

Detailed Description of the Invention

Definitions

5 As used herein, and unless stated otherwise, each of the following terms shall have the definition set forth below.

"Administering" shall mean administering according to any
10 of the various methods and delivery systems known to those skilled in the art. The administering can be performed, for example, via implant, transmucosally, transdermally and subcutaneously. In the preferred embodiment, the administering is topical and preferably
15 dermal.

"Catalytic" shall mean the functioning of an agent as a catalyst, i.e. an agent that increases the rate of a chemical reaction without itself undergoing a permanent
20 structural change.

"Consensus sequence" shall mean a nucleotide sequence of at least two residues in length between which catalytic nucleic acid cleavage occurs. For example, consensus
25 sequences include "A:C" and "G:U".

"Hairless Protein" shall mean the protein encoded by the nucleotide sequence shown in Figures 1A - 1C (SEQ ID NO:1) and having the amino acid sequence shown in SEQ ID
30 NO:17, and any variants thereof, whether artificial or naturally occurring. Variants include, without limitation, homologues, post-translational modifications, mutants such as those commonly referred to as T1022A, 1256delC, 1261del21, R620Q, 2001delCCAG, 2776+1G→A,
35 N970K, V1136D, 3434delC and 2147delC, and polymorphisms

such as the one commonly referred to as L526P.

"Hairless Protein mRNA" shall mean any mRNA molecule comprising a sequence which encodes Hairless Protein.
5 Hairless Protein mRNA includes, without limitation, protein-encoding sequences as well as the 5' and 3' non-protein-encoding sequences. An example of Hairless Protein mRNA is the mRNA sequence shown in Figure 1. As used herein, the terms "Hairless Protein", "Hairless",
10 "hairless protein" and "hairless" are used interchangeably, unless stated otherwise.

"Hybridize" shall mean the annealing of one single-stranded nucleic acid molecule to another nucleic
15 acid molecule based on sequence complementarity. The propensity for hybridization between nucleic acids depends on the temperature and ionic strength of their milieu, the length of the nucleic acids and the degree of complementarity. The effect of these parameters on
20 hybridization is well known in the art (see Sambrook, 1989).

"Inhibit" shall mean to slow, stop or otherwise impede.

25 "Nucleic acid molecule" shall mean any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids thereof. The nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T and U, as well as derivatives thereof. Derivatives of these bases are
30 well known in the art, and are exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, New Jersey, USA).

35 "Pharmaceutically acceptable carrier" shall mean any of

the various carriers known to those skilled in the art. In one embodiment, the carrier is an alcohol, preferably ethylene glycol. In another embodiment, the carrier is a liposome. The following pharmaceutically acceptable
5 carriers are set forth, in relation to their most commonly associated delivery systems, by way of example, noting the fact that the instant pharmaceutical compositions are preferably delivered dermally.

10 Dermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as
15 solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrrolidone). In one embodiment, the pharmaceutically acceptable carrier is a liposome or a
20 transdermal enhancer. Examples of liposomes which can be used in this invention include the following: (1) CellFectin, 1:1.5 (M/M) liposome formulation of the cationic lipid N,N_I,N_{II},N_{III}-tetramethyl-N,N_I,N_{II},N_{III}-tetrapalmitoyl-spermine and dioleoyl phosphatidylethanol-
25 amine (DOPE) (GIBCO BRL); (2) Cytofectin GSV, 2:1 (M/M) liposome formulation of a cationic lipid and DOPE (Glen Research); (3) DOTAP (N-[1-(2,3-dioleoyloxy)-N,N,N-trimethyl-ammonium]methanesulfate) (Boehringer Mannheim); and
30 (4) Lipofectamine, 3:1 (M/M) liposome formulation of the polycationic lipid DOSPA and the neutral lipid DOPE (GIBCO BRL).

Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels and creams, and can
35 contain excipients such as solubilizers and enhancers

(e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid).

5

Injectable drug delivery systems include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol and sucrose) and polymers (e.g., polycaprylactones and PLGA's). Implantable systems include rods and discs, and can contain excipients such as PLGA and polycaprylactone.

15 Oral delivery systems include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrrolidone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc).

25 "Specifically cleave", when referring to the action of one of the instant catalytic nucleic acid molecules on a target mRNA molecule, shall mean to cleave the target mRNA molecule without cleaving another mRNA molecule lacking a sequence complementary to either of the catalytic nucleic acid molecule's two binding domains.

30

"Subject" shall mean any animal, such as a human, a primate, a mouse, a rat, a guinea pig or a rabbit.

"Vector" shall include, without limitation, a nucleic acid molecule that can be used to stably introduce a

specific nucleic acid sequence into the genome of an organism.

Finally, the following abbreviations shall have the meanings set forth below: "A" shall mean Adenine; "bp" shall mean base pairs; "C" shall mean Cytosine; "DNA" shall mean deoxyribonucleic acid; "G" shall mean Guanine; "mRNA" shall mean messenger ribonucleic acid; "RNA" shall mean ribonucleic acid; "RT-PCR" shall mean reverse transcriptase polymerase chain reaction; "RY" shall mean purine:pyrimidine; "T" shall mean Thymine; and "U" shall mean Uracil.

Embodiments of the Invention

This invention provides a catalytic deoxyribonucleic acid molecule that specifically cleaves Hairless Protein mRNA comprising:

- (a) a catalytic domain that cleaves mRNA at a defined consensus sequence;
- (b) a binding domain contiguous with the 5' end of the catalytic domain; and
- (c) a binding domain contiguous with the 3' end of the catalytic domain,

wherein the binding domains are complementary to, and therefore hybridize with, the two regions flanking the defined consensus sequence within the Hairless Protein mRNA at which cleavage is desired, and wherein each binding domain is at least 4 residues in length, and both binding domains have a combined total length of at least 8 residues. In the preferred embodiment, each binding domain is 7 residues in length, and both binding domains have a combined total length of 14 residues.

The catalytic domain may optionally contain stem-loop

structures in addition to the nucleotides required for catalytic activity. In one embodiment of the instant catalytic deoxyribonucleic acid molecule, the catalytic domain has the sequence ggctagctacaacga (SEQ ID NO:18),
 5 and cleaves mRNA at the consensus sequence purine:pyrimidine. In a preferred embodiment, cleavage occurs at one or more of the following cleavage sites in the Hairless Protein mRNA (shown in Figures 1A - 1C and SEQ ID NO:1), wherein the indicated nucleotide residue
 10 immediately precedes the cleavage site: 1594, 1597, 1641, 1698, 1732, 1750, 1801, 1811, 2028, 2033, 2047, 2083, 2269, 2380 and 2395.

In another embodiment the instant deoxyribonucleic acid
 15 molecule has a sequence selected from the group consisting of:

- (a) cccatggggctagctacaacgagcagtcc (SEQ ID NO:2);
- (b) cggcccaggctagctacaacgaggtgcag (SEQ ID NO:3);
- 20 (c) ctcaggaggctagctacaacgagcccctc (SEQ ID NO:4);
- (d) gggagcaggctagctacaacgagtccttg (SEQ ID NO:5);
- (e) ctccccaggctagctacaacgatctgggg (SEQ ID NO:6);
- (f) cagccagggctagctacaacgatgacctt (SEQ ID NO:7);
- (g) cagcggaggctagctacaacgagggtaag (SEQ ID NO:8);
- 25 (h) cgcagaaggctagctacaacgagccagcg (SEQ ID NO:9);
- (i) tgcggggggctagctacaacgacaggggc (SEQ ID NO:10);
- (j) aggggtgggctagctacaacgaggggtca (SEQ ID NO:11);
- (k) cccggagggctagctacaacgaataccca (SEQ ID NO:12);
- (l) gcctaagggctagctacaacgatgaaggc (SEQ ID NO:13);
- 30 (m) gcaaggaggctagctacaacgatctgctg (SEQ ID NO:14);
- (n) gttcccaggctagctacaacgacgcctgg (SEQ ID NO:15); and
- (o) cagctggggctagctacaacgaaccaag (SEQ ID NO:16).

This invention also provides a catalytic ribonucleic acid
 35 molecule that specifically cleaves Hairless Protein mRNA

comprising:

- (a) a catalytic domain that cleaves mRNA at a defined consensus sequence;
- 5 (b) a binding domain contiguous with the 5' end of the catalytic domain; and
- (c) a binding domain contiguous with the 3' end of the catalytic domain,

wherein the binding domains are complementary to, and therefore hybridize with, the two regions flanking the
10 defined consensus sequence within the Hairless Protein mRNA at which cleavage is desired, and wherein each binding domain is at least 4 residues in length and both binding domains have a combined total length of at least 8 residues.

15

In one embodiment of the instant catalytic ribonucleic acid molecule, each binding domain is at least 12 residues in length. In the preferred embodiment, each binding domain is no more than 17 residues in length. In
20 another embodiment, both binding domains have a combined total length of at least 24 residues, and no more than 34 residues.

Preferably, the instant catalytic ribonucleic acid
25 molecule is a hammerhead ribozyme. Hammerhead ribozymes are well known in the literature, as described in Pley et al, 1994. In one embodiment, the consensus sequence is the sequence 5'-NUH-3', where N is any nucleotide, U is uridine and H is any nucleotide except guanine. An
30 example of such sequence is 5'-adenine:uracil:adenine-3'. In another embodiment, the catalytic domain has the sequence ctgatgagtcctgaggacgaaaca (SEQ ID NO:19).

In this invention, the instant catalytic nucleic acid
35 molecules can cleave Hairless Protein mRNA at each and

any of the consensus sequences therein. Since ribozyme and DNAzyme consensus sequences are known, and the Hairless Protein mRNA sequence is known, one of ordinary skill could readily construct a catalytic nucleic acid molecule directed to any of the Hairless Protein mRNA consensus sequences based on the instant specification. In a preferred embodiment, the cleavage occurs at one or more of the following cleavage sites in Hairless Protein mRNA (sequence shown in Figures 1A - 1C and SEQ ID NO:1), wherein the indicated nucleotide residue immediately precedes the cleavage site: -94, 159, 264, 506, 847 and 879. The number -94 indicates a target site upstream from the 5' end of the sequence shown in Figure 1, in the 5' untranslated region of the sequence.

In another embodiment, the instant catalytic ribonucleic acid molecule has a sequence selected from the group consisting of:

- (a) cggccggcgggcgagctgatgagtcggtgaggacgaaacacgcgttctcc cgctct (SEQ ID NO:20);
- (b) gagtctggggtgctcagctgatgagtcggtgaggacgaaacacgcccctc caaaaagg (SEQ ID NO:21);
- (c) ttgctgcccagccagttctgatgagtcggtgaggacgaaacaccttctc tccccatt (SEQ ID NO:22);
- (d) gctctgggggcaggccactgatgagtcggtgaggacgaaacacactaggt aggggtggc (SEQ ID NO:23);
- (e) atgaacaaggcctggggctgatgagtcggtgaggacgaaacacaagcggg ccaggagg (SEQ ID NO:24); and
- (f) tcgcctggcccagcccactgatgagtcggtgaggacgaaacacgttgcca agagtatg (SEQ ID NO:25).

In an alternative embodiment of the instant catalytic ribonucleic acid molecule, the molecule is a hairpin ribozyme. Hairpin ribozymes are well known in the literature as described in Fedor (2000).

Catalytic nucleic acid molecules can be directed to any cleavage site within the Hairless Protein mRNA, preferably within the 5' half of the mRNA. In one embodiment the cleavage site within the hairless protein mRNA is located within the first 3000 residues following the mRNA's 5' terminus. In another embodiment cleavage occurs within the first 1500 residues. Here, "following" means in the 3' direction of the 5' terminus.

10

The Hairless Protein mRNA cleaved by the instant catalytic nucleic acid molecules can be from any subject. In one embodiment, the Hairless Protein mRNA is from a subject selected from the group consisting of human, monkey, rat and mouse, and in the preferred embodiment is human. In the preferred embodiment, the Hairless Protein mRNA has the sequence shown in Figures 1A - 1C.

15

This invention also provides a first pharmaceutical composition comprising the instant catalytic ribonucleic acid molecule or deoxyribonucleic acid molecule and a pharmaceutically acceptable carrier.

20

This invention further provides a method of specifically cleaving Hairless Protein mRNA comprising contacting the mRNA with either of the instant catalytic nucleic acid molecules under conditions permitting the molecule to cleave the mRNA. These conditions are well known in the art and include physiological conditions.

25

30

This invention further provides a method of specifically cleaving Hairless Protein mRNA in a cell, comprising contacting the cell containing the mRNA with either of the instant catalytic nucleic acid molecules so as to specifically cleave the hairless protein mRNA in the

35

cell. The cell containing Hairless Protein mRNA can be, for example, a naturally occurring cell or a transgenic cell. In the preferred embodiment, the cell is a keratinocyte.

5

This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a cell that would otherwise express Hairless Protein, comprising contacting the cell with either of the instant catalytic nucleic acid molecules so as to specifically inhibit the expression of Hairless Protein in the cell.

This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising administering to the subject an amount of either of the instant catalytic nucleic acid molecules effective to specifically inhibit the expression of Hairless Protein in the subject's cells.

This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising administering to the subject an amount of the first pharmaceutical composition effective to specifically inhibit the expression of Hairless Protein in the subject's cells.

Determining the effective amount of the instant pharmaceutical composition can be done based on animal data using routine computational methods. In one embodiment, the effective amount contains between about 10 ng and about 100 μ g of the instant nucleic acid molecules per square centimeter of skin. In another embodiment, the effective amount contains between about 100 ng and about 10 μ g of the nucleic acid molecules per square centimeter of skin. In a further embodiment, the

effective amount contains between about 1 μg and about 5 μg , and preferably about 2 μg , of the nucleic acid molecules per square centimeter of skin.

- 5 This invention further provides a method of inhibiting hair production by a hair-producing cell comprising contacting the cell with an effective amount of either of the instant catalytic nucleic acid molecules.
- 10 This invention further provides a method of inhibiting hair growth in a subject comprising administering to the subject an effective amount of the first pharmaceutical composition.
- 15 Hair follicles are dynamic structures that generate hair through a regulated cycle of growth and remodeling. The hair follicle cycles between rest (telogen), growth (anagen) and regression (catagen). This invention further provides a method of inhibiting the transition of a hair
- 20 follicle from the anagen phase to the catagen phase comprising contacting the follicle with an effective amount of either of the instant catalytic nucleic acid molecules or the first pharmaceutical composition.
- 25 This invention further provides a vector which comprises a sequence encoding either of the instant catalytic nucleic acid molecules.

- This invention further provides a host-vector system
- 30 comprising a cell having the instant vector therein. This invention still further provides a method of producing either of the instant catalytic nucleic acid molecules comprising culturing a cell having therein a vector comprising a sequence encoding either catalytic nucleic
- 35 acid molecule under conditions permitting the expression

of the catalytic nucleic acid molecule by the cell. Methods of culturing cells in order to permit expression and conditions permitting expression are well known in the art. For example see Sambrook et al. (1989). Such
5 methods can optionally comprise a further step of recovering the nucleic acid product.

This invention provides a nucleic acid molecule that specifically hybridizes to Hairless Protein mRNA so as to
10 inhibit the translation thereof in a cell.

In one embodiment, the instant nucleic acid is a ribonucleic acid. In another embodiment the nucleic acid is deoxyribonucleic acid.
15

The invention further provides a second pharmaceutical composition comprising (a) the instant nucleic acid molecule or the instant vector and (b) a pharmaceutically acceptable carrier.
20

This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a cell that would otherwise express Hairless Protein, comprising contacting the cell with the instant nucleic acid
25 molecule so as to specifically inhibit the expression of Hairless Protein in the cell.

This invention further provides a method of specifically inhibiting the expression of Hairless Protein in a
30 subject's cells comprising administering to the subject an amount of the instant nucleic acid molecule effective to specifically inhibit the expression of Hairless Protein in the subject's cells.

35 This invention further provides a method of specifically

inhibiting the expression of Hairless Protein in a subject's cells comprising administering to the subject an amount of the second pharmaceutical composition effective to specifically inhibit the expression of
5 Hairless Protein in the subject's cells.

This invention further provides a method of inhibiting hair production by a hair-producing cell comprising contacting the cell with an effective amount of the
10 instant nucleic acid molecule.

This invention further provides a method of inhibiting hair growth in a subject comprising administering to the subject an effective amount of the second pharmaceutical
15 composition.

This invention further provides a method of inhibiting the transition of a hair follicle from the anagen phase to the catagen phase comprising contacting the follicle
20 with an effective amount of the instant nucleic acid molecule or the second pharmaceutical composition.

This invention further provides a method of producing the instant nucleic acid molecule comprising culturing a cell
25 having therein a vector comprising a sequence encoding said nucleic acid molecule under conditions permitting the expression of the nucleic acid molecule by the cell.

Finally this invention provides a non-human transgenic
30 mammal, wherein the mammal's genome:

- (a) has stably integrated therein a nucleotide sequence encoding a human Hairless Protein operably linked to a promoter, whereby the nucleotide sequence is expressed; and
- 35 (b) lacks an expressible endogenous Hairless Protein-

encoding nucleic acid sequence.

In the preferred embodiment, the transgenic mammal is a mouse. The instant transgenic mammal is useful as a model
5 for testing hair removal products which function by inhibiting Hairless Protein expression.

In this invention, the various embodiments of subjects, pharmaceutically acceptable carriers, dosages, cell
10 types, routes of administration and target nucleic acid sequences are envisioned for each of the instant nucleic acid molecules, pharmaceutical compositions and methods. Moreover, in this invention, the various embodiments of methods, subjects, pharmaceutically acceptable carriers,
15 dosages, cell types, routes of administration and target nucleic acid sequences are envisioned for all non-nucleic acid agents which inhibit the expression of Hairless Protein. Such non-nucleic acid agents include, without limitation, polypeptides, carbohydrates and small organic
20 compounds.

This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific
25 experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.

Experimental Details

Part I - Catalytic Nucleic Acids

5 Introduction

Catalytic nucleic acid technology is widely used to target mRNA in a sequence-specific fashion, and thus change the expression pattern of cells or tissues. While
10 the goal of mRNA targeting is usually the cleavage of mutant mRNA with the prospect of gene therapy for inherited diseases, in certain instances targeting of wild-type genes can be used therapeutically.

15 Lack of expression of the mouse hairless gene due to inherited mutations leads to the complete loss of hair, known as atrichia. This study was designed to recapitulate the hairless phenotype in a restricted manner by topical application of deoxy-ribozyme molecules
20 to specifically cleave the mouse hairless mRNA. Pathology samples taken from the treated area at different times demonstrated a decreased number of hair follicles, involution of the remaining follicles, separation of the dermal papillae and the presence of dermal cysts, all
25 characteristics of the hairless phenotype but not normally present in the skin of C57Bl/6J mice.

In this study, the hairless phenotype is successfully recapitulated using topically applied target-specific
30 catalytic oligonucleotides designed to cleave the mouse hairless mRNA. Hence, this invention demonstrates the feasibility of using ribozyme and deoxy-ribozyme technology to alter gene expression in the skin via topical application and provide permanent hair removal.

35

Materials and Methods

Deoxy-ribozyme design and in vitro testing. To target the
5 mouse hairless mRNA, a series of deoxy-ribozymes were
designed based on the consensus cleavage sites 5'-RY-3'
in the mRNA sequence (GenBank Accession#: AF039196) (Ahmad
et al. 1998a). Only those potential cleavage sites which
were located on an open loop of the mRNA according to the
10 RNA folding software RNADraw 2.1 were targeted (Matzura
and Wennborg 1996). The deoxy-ribozyme design utilized
the previously described structure (Santoro and Joyce
1997; Santoro and Joyce 1998) where two sequence-specific
arms were attached to a catalytic core based on the mouse
15 hairless mRNA sequence. The deoxy-ribozymes were custom
synthesized (Life Technologies). Commercially available
mouse brain polyA-RNA (Ambion) served as a template in
the *in vitro* cleavage reaction to test the efficiency of
the deoxy-ribozymes. 800 ng RNA template were incubated
20 in the presence of 20mM Mg²⁺ and RNase Out RNase inhibitor
(Life Technologies) at pH 7.5 with 2 µg deoxy-ribozyme
for one hour. After incubation, aliquots of the reaction
were used as templates for RT-PCR, amplifying regions
including the targeted cleavage sites. The RT-PCR
25 products were visualized on an ethidium bromide-
containing 2% agarose gel under UV light, and the
intensity of the products was determined as described
above (Figure 3). Those deoxy-ribozymes that were capable
of cleaving the target mouse hairless mRNA with the
30 highest efficiency were used for *in vivo* experiments
(Figure 3, lanes 1, 3).

Deoxy-ribozyme treatment schedule. Newborn C57Bl/6J mice
were treated with a deoxy-ribozyme formula twice a day
35 starting on the first day after delivery. As the mice

started to grow hair, hair shafts were regularly shortened using an electric clipper to make the skin surface accessible and to enhance the penetration of the treatment formula. For each treatment, 2 μ g deoxy-ribozyme, dissolved in a 85% EtOH and 15% ethylene glycol vehicle, were applied to a one square centimeter area on the back. During application and for a fifteen minute period after, the mice were placed in temporary restraint to prevent removal of the formula. Control animals were treated with vehicle containing oligonucleotides of the same length but of random sequence. The treatment continued until the mice were sacrificed for evaluation.

Biopsy Procedures and Pathology. The mice were humanely euthanized after 28 days, 35 days or 8 weeks of treatment. The entire treatment area, together with an equal sized non-treated neighboring area of skin, were removed, fixed in formalin solution, embedded and processed for pathology using standard procedures.

20

Results

To evaluate the feasibility of using topically applied deoxy-ribozymes for selective ablation of genes expressed in the hair follicle, a model system was used to recapitulate the hairless mouse phenotype. After secondary structure based target-site selection, the choices were narrowed for targeting oligonucleotides using a novel *in vitro* cleavage assay (Cserhalmi-Friedman et al. manuscript in preparation). The three deoxy-ribozymes that proved to be the most efficient in cutting full-length mouse hairless mRNA *in vitro* were used for the *in vivo* experiments.

35 After continuous treatment, by day 20 the hair of the

treated animals became visibly sparse on the treated area. Pathology specimens taken from the treated area at day 28 (see Figures 2A - 2D) demonstrated (i) a decreased number of hair follicles, (ii) several dense, basophilic cell groups in the dermis corresponding to dermal papillae by morphology and localization, and (iii) an absence of surrounding epithelial hair follicle tissues and related hair follicles. The remaining hair follicles were in telogen phase, in sharp contrast with the advanced anagen follicles of the surrounding untreated skin and the skin of the untreated control animals.

Samples taken from the treated area at day 35 showed a different result. Some follicles in telogen phase could be observed, although they were more sparse than in the surrounding untreated area or in the samples from the untreated control animals. In the dermis of the treated region, large epithelial cysts filled with amorphous material were noticed, which corresponded to dermal cysts. These characteristics, the arrest of hair cycling, involution of hair follicles, detachment of dermal papillae and development of dermal cysts are not normally present in C57Bl/6J mice, but represent the cardinal features of the skin of the hairless mouse.

The data revealed here demonstrate that by using topically applied catalytic oligonucleotides, a key player of hair follicle regulation can be eliminated and hair follicle cycling can be disrupted. These results serve not only as a proof of principle for future use of this approach for hair removal, but also demonstrate the feasibility of using topical catalytic nucleic acid technology to successfully change the gene expression pattern of hair follicle cells at the mRNA level, and thus influence the hair phenotype.

Part II - Antisense Nucleic Acids

Antisense oligodeoxynucleotides were synthesized as directed to the inhibition of Hairless expression based on the Hairless mRNA sequence (SEQ ID NO:1). Cos-1 cells were transfected with the pEGFP full-length Hairless construct, and cells were harvested 16 hours after transfection. Total protein lysate was analyzed on a 10% SDS PAGE gel and transferred to nitrocellulose. Hairless protein was detected using an anti-Hairless polyclonal antibody raised against a C-terminal peptide. In a negative control, cells not transfected with the full-length Hairless construct showed no Hairless expression. Hairless expression was clearly observed in positive control experiments when antisense oligodeoxynucleotides were not added. Experiments where anti-Hairless antisense oligonucleotides (i.e. ODN1: 5' GCTGGGCATACTCTCCAT 3' (SEQ ID NO:26) and ODN2: 5' CATCACTCTCCTGCCCTC 3' (SEQ ID NO:27)) were added to the medium at 40 μ M concentration prior to the transfection clearly showed an absence of Hairless expression, demonstrating antisense oligodeoxynucleotide inhibition of the Hairless gene product (see Figure 4).

References

- Ahmad W, Faiyaz ul Haque M, Brancolini V, Tsou HC, ul Haque S, Lam H, Aita VM, Owen J, deBlaquiere M, Frank J,
5 Cserhalmi-Friedman PB, Leask A, McGrath JA, Peacocke M, Ahmad M, Ott J, Christiano AM (1998a) Alopecia universalis associated with a mutation in the human hairless gene. *Science* 279:720-4.
- 10 Ahmad W, Panteleyev AA, Henson-Apollonio V, Sundberg JP, Christiano AM (1998b) Molecular basis of a novel rhino (hr(rhChr)) phenotype: a nonsense mutation in the mouse hairless gene. *Exp Dermatol* 7:298-301.
- 15 Bartel DP (1999) Creation and evolution of new ribozymes. *Biol Bull* 196:322-3.
- Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D, Engelke
20 D, Rossi JJ (1997) The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. *RNA* 3:75-88.
- 25 Cairns MJ, King A, Sun LQ (2000) Nucleic acid mutation analysis using catalytic DNA. *Nucleic Acids Res* 28:E9.
- Cech TR (1987) The chemistry of self-splicing RNA and RNA
30 enzymes. *Science* 236:1532-9.
- Fedor MJ (2000) Structure and Function of the Hairpin Ribozyme. *J Mol Biol* 297 (2):269-91.
- Flory CM, Pavco PA, Jarvis TC, Lesch ME, Wincott FE,
35 Beigelman L, Hunt SW, 3rd, Schrier DJ (1996) Nuclease-

resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. *Proc Natl Acad Sci USA* 93:754-8.

- 5 Long MB, Sullenger BA (1999) Evaluating group I intron catalytic efficiency in mammalian cells. *Mol Cell Biol* 19: 6479-87.

Matzura O, Wennborg A (1996) RNAdraw: an integrated
10 program for RNA secondary structure calculation and analysis under 32-bit Microsoft Windows. *Comput Appl Biosci* 12:247-9.

Michienzi A, Prislei S, Bozzoni I (1996) U1 small nuclear
15 RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. *Proc Natl Acad Sci USA* 93:7219-24.

Montgomery RA, Dietz HC (1997) Inhibition of fibrillin 1
20 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. *Hum Mol Genet* 6:519-25.

Panteleyev AA, Ahmad W, Malashenko AM, Ignatieva EL, Paus
25 R, Sundberg JP, Christiano AM (1998a) Molecular basis for the rhino Yurlovo (hr(rhY)) phenotype: severe skin abnormalities and female reproductive defects associated with an insertion in the hairless gene. *Exp Dermatol* 7: 281-8.

30 Panteleyev AA, Paus R, Ahmad W, Sundberg JP, Christiano AM (1998b) Molecular and functional aspects of the hairless (hr) gene in laboratory rodents and humans. *Exp Dermatol* 7:249-67.

35

Parthasarathy R, Cote GJ, Gagel RF (1999) Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. *Cancer Res* 59:3911-4.

- 5 Pley et al, (1994) Three-dimensional structure of a hammerhead ribozyme. *Nature* 372:68-74.

Phylactou LA, Kilpatrick MW, Wood MJ (1998) Ribozymes as therapeutic tools for genetic disease. *Hum Mol Genet* 7:
10 1649-53.

Sambrook et al., "Molecular Cloning: A Laboratory Manual", Second Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

15

Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A, Atkins DG, Khachigian LM (1999) New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. *Nat Med* 5:1438.

20

Santoro SW, Joyce GF (1997) A general purpose RNA-cleaving DNA enzyme. *Proc Natl Acad Sci USA* 94:4262-6.

Santoro SW, Joyce GF (1998) Mechanism and utility of an
25 RNA-cleaving DNA enzyme. *Biochemistry* 37:13330-42.

Sioud M (1996) Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor- alpha production by peritoneal cells in vitro and in vivo. *Eur J Immunol* 26:
30 1026-31.

Sioud M, Drlica K (1991) Prevention of human immunodeficiency virus type 1 integrase expression in *Escherichia coli* by a ribozyme. *Proc Natl Acad Sci USA*
35 88: 7303-7.

Vaish NK, Kore AR, Eckstein F (1998) Recent developments in the hammerhead ribozyme field. *Nucleic Acids Res* 26: 5237-42.

5

What is claimed is:

1. A catalytic deoxyribonucleic acid molecule that specifically cleaves Hairless Protein mRNA comprising:
 - (a) a catalytic domain that cleaves mRNA at a defined consensus sequence;
 - (b) a binding domain contiguous with the 5' end of the catalytic domain; and
 - (c) a binding domain contiguous with the 3' end of the catalytic domain,
 wherein the binding domains are complementary to, and therefore hybridize with, the two regions flanking the defined consensus sequence within the Hairless Protein mRNA at which cleavage is desired, and wherein each binding domain is at least 4 residues in length and both binding domains have a combined total length of at least 8 residues.
2. The catalytic deoxyribonucleic acid molecule of claim 1, wherein the catalytic domain has the sequence ggctagctacaacga (SEQ ID NO:18), and cleaves mRNA at the consensus sequence purine:pyrimidine.
3. The catalytic deoxyribonucleic acid molecule of claim 2, wherein the molecule has a sequence selected from the group consisting of:
 - (a) cccatggggctagctacaacgagcagtc (SEQ ID NO:2);
 - (b) cggcccaggctagctacaacgaggtgcag (SEQ ID NO:3);
 - (c) ctcaggaggctagctacaacgagcccctc (SEQ ID NO:4);
 - (d) gggagcaggctagctacaacgagtccttg (SEQ ID NO:5);
 - (e) ctccccaggctagctacaacgatctgggg (SEQ ID NO:6);
 - (f) cagccagggctagctacaacgatgacctt (SEQ ID NO:7);
 - (g) cagcggaggctagctacaacgagggtaag (SEQ ID NO:8);

- (h) cgcagaaggctagctacaacgagccagcg (SEQ ID NO:9);
 (i) tgcggggggctagctacaacgacaggggc (SEQ ID NO:10);
 (j) aggggtgggctagctacaacgaggggtca (SEQ ID NO:11);
 (k) cccggagggctagctacaacgaataccca (SEQ ID NO:12);
 5 (l) gcctaagggctagctacaacgatgaaggc (SEQ ID NO:13);
 (m) gcaaggaggctagctacaacgatctgctg (SEQ ID NO:14);
 (n) gttcccaggctagctacaacgacgcttg (SEQ ID NO:15);
 and
 (o) cagctggggctagctacaacgaaccaag (SEQ ID NO:16).
- 10
4. A catalytic ribonucleic acid molecule that specifically cleaves Hairless Protein mRNA comprising:
- (a) a catalytic domain that cleaves mRNA at a
 15 defined consensus sequence;
- (b) a binding domain contiguous with the 5' end of the catalytic domain; and
- (c) a binding domain contiguous with the 3' end of the catalytic domain,
- 20 wherein the binding domains are complementary to, and therefore hybridize with, the two regions flanking the defined consensus sequence within the Hairless Protein mRNA at which cleavage is desired, and wherein each binding domain is at least 4
- 25 residues in length and both binding domains have a combined total length of at least 8 residues.
5. The catalytic ribonucleic acid molecule of claim 4, wherein the molecule is a hammerhead ribozyme.
- 30
6. The catalytic ribonucleic acid molecule of claim 4, wherein the catalytic domain has the sequence ctgatgagtccgtgaggacgaaaca (SEQ ID NO:19), and cleaves mRNA at the consensus sequence 5'-NUH-3'.
- 35

7. The catalytic ribonucleic acid molecule of claim 6, wherein the catalytic ribonucleic acid molecule has a sequence selected from the group consisting of:

- 5 (a) cggccggcgggcgagctgatgagtcggtgaggacgaaaca
cgcggttctcccgtct (SEQ ID NO:20);
(b) gagtctggggtgctcagctgatgagtcggtgaggacgaaa
cacgcccctcaaaaagg (SEQ ID NO:21);
(c) ttgctgcccagccagttctgatgagtcggtgaggacgaaa
10 caccttcctctcccccatt (SEQ ID NO:22);
(d) gctctgggggcaggccactgatgagtcggtgaggacgaaa
cacactaggtagggtggc (SEQ ID NO:23);
(e) atgaacaaggcctggggctgatgagtcggtgaggacgaaa
cacaagcgggccaggagg (SEQ ID NO:24); and
15 (f) tcgcctggcccagcccactgatgagtcggtgaggacgaaa
cacggttccaagagtatg (SEQ ID NO:25).

8. The catalytic ribonucleic acid molecule of claim 4, wherein the molecule is a hairpin ribozyme.

20

9. The catalytic nucleic acid molecule of claim 1 or 4, wherein the cleavage site within the Hairless Protein mRNA is located within the first 3000 residues following the mRNA's 5' terminus.

25

10. The catalytic nucleic acid molecule of claim 9, wherein the cleavage site within the Hairless Protein mRNA is located within the first 1500 residues following the mRNA's 5' terminus.

30

11. The catalytic nucleic acid molecule of claim 1 or 4, wherein the Hairless Protein mRNA is from a subject selected from the group consisting of human, monkey, rat and mouse.

35

12. The catalytic nucleic acid molecule of claim 1 or 4, wherein the Hairless Protein mRNA has the sequence shown in Figures 1A - 1C (SEQ ID NO:1).
- 5 13. A pharmaceutical composition comprising the catalytic nucleic acid molecule of claim 1 or 4 and a pharmaceutically acceptable carrier.
- 10 14. The pharmaceutical composition of claim 13, wherein the carrier is an alcohol.
- 15 15. The pharmaceutical composition of claim 14, wherein the carrier is ethylene glycol.
- 15 16. The pharmaceutical composition of claim 13, wherein the carrier is a liposome.
- 20 17. A method of specifically cleaving Hairless Protein mRNA comprising contacting the mRNA with the catalytic nucleic acid molecule of claim 1 or 4 under conditions permitting the molecule to cleave the mRNA.
- 25 18. A method of specifically cleaving Hairless Protein mRNA in a cell, comprising contacting the cell containing the mRNA with the catalytic nucleic acid molecule of claim 1 or 4 so as to specifically cleave the Hairless Protein mRNA in the cell.
- 30 19. A method of specifically inhibiting the expression of Hairless Protein in a cell that would otherwise express Hairless Protein, comprising contacting the cell with the catalytic nucleic acid molecule of claim 1 or 4 so as to specifically inhibit the expression of Hairless Protein in the cell.
- 35

20. A method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising administering to the subject an amount of the catalytic nucleic acid molecule of claim 1 or 4
5 effective to specifically inhibit the expression of Hairless Protein in the subject's cells.
21. A method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising
10 administering to the subject an amount of the pharmaceutical composition of claim 13 effective to specifically inhibit the expression of Hairless Protein in the subject's cells.
22. A method of inhibiting hair production by a hair-producing cell comprising contacting the cell with an effective amount of the catalytic nucleic acid of claim 1 or 4.
23. A method of inhibiting hair growth in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 13.
24. A method of inhibiting the transition of a hair follicle from the anagen phase to the catagen phase comprising contacting the follicle with an effective amount of the catalytic nucleic acid of claim 1 or 4.
25. A method of inhibiting the transition of a hair follicle from the anagen phase to the catagen phase comprising contacting the follicle with an effective amount of the pharmaceutical composition of claim 13.

26. The method of claim 18, wherein the cell is a keratinocyte.
27. The method of claim 19, wherein the cell is a
5 keratinocyte.
28. The method of claim 20, wherein the cell is a keratinocyte.
- 10 29. The method of claim 21, wherein the cell is a keratinocyte.
30. The method of claim 22, wherein the cell is a keratinocyte.
- 15 31. The method of claim 20, wherein the subject is a human.
32. The method of claim 21, wherein the subject is a
20 human.
33. The method of claim 23, wherein the subject is a human.
- 25 34. The method of claim 20, wherein the catalytic nucleic acid molecule is administered topically.
35. The method of claim 34, wherein the catalytic nucleic acid is administered dermally.
- 30 36. The method of claim 21, wherein the pharmaceutical composition is administered topically.
- 35 37. The method of claim 36, wherein the pharmaceutical composition is administered dermally.

38. The method of claim 23, wherein the pharmaceutical composition is administered topically.
39. The method of claim 38, wherein the pharmaceutical composition is administered dermally.
40. A vector which comprises a sequence encoding the catalytic nucleic acid molecule of claim 1 or 4.
41. A host-vector system comprising a cell having the vector of claim 40 therein.
42. A method of producing the catalytic nucleic acid molecule of claim 1 or 4 comprising culturing a cell having therein a vector comprising a sequence encoding said catalytic nucleic acid molecule under conditions permitting the expression of the catalytic nucleic acid molecule by the cell.
43. A nucleic acid molecule that specifically hybridizes to Hairless Protein mRNA so as to inhibit the translation thereof in a cell.
44. The nucleic acid of claim 43, wherein the nucleic acid is a ribonucleic acid.
45. The nucleic acid of claim 43, wherein the nucleic acid is deoxyribonucleic acid.
46. The nucleic acid molecule of claim 43, wherein the molecule hybridizes to a site within the Hairless Protein mRNA located within the first 3000 residues following the mRNA's 5' terminus.
47. The nucleic acid molecule of claim 46, wherein the

molecule hybridizes to a site within the Hairless Protein mRNA located within the first 1500 residues following the mRNA's 5' terminus.

- 5 48. The ribonucleic acid molecule of claim 43, wherein the Hairless Protein mRNA is from a subject selected from the group consisting of human, monkey, rat and mouse.
- 10 49. The ribonucleic acid molecule of claim 43, wherein the Hairless Protein mRNA has the sequence shown in Figures 1A - 1C (SEQ ID NO:1).
- 15 50. A vector which comprises a sequence encoding the nucleic acid molecule of claim 43.
51. A host-vector system comprising a cell having the vector of claim 50 therein.
- 20 52. A pharmaceutical composition comprising (a) the nucleic acid molecule of claim 43 or the vector of claim 50 and (b) a pharmaceutically acceptable carrier.
- 25 53. The pharmaceutical composition of claim 52, wherein the carrier is an alcohol.
54. The pharmaceutical composition of claim 53, wherein the carrier is ethylene glycol.
- 30 55. The pharmaceutical composition of claim 52, wherein the carrier is a liposome.
- 35 56. A method of specifically inhibiting the expression of Hairless Protein in a cell that would otherwise

express Hairless Protein, comprising contacting the cell with the nucleic acid molecule of claim 43 so as to specifically inhibit the expression of Hairless Protein in the cell.

- 5
57. A method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising administering to the subject an amount of the nucleic acid molecule of claim 43 effective to
- 10 specifically inhibit the expression of Hairless Protein in the subject's cells.
58. A method of specifically inhibiting the expression of Hairless Protein in a subject's cells comprising
- 15 administering to the subject an amount of the pharmaceutical composition of claim 52 effective to specifically inhibit the expression of Hairless Protein in the subject's cells.
- 20 59. A method of inhibiting hair production by a hair-producing cell comprising contacting the cell with an effective amount of the nucleic acid molecule of claim 43.
- 25 60. A method of inhibiting hair growth in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.
- 30 61. A method of inhibiting the transition of a hair follicle from the anagen phase to the catagen phase comprising contacting the follicle with an effective amount of the nucleic acid molecule of claim 43.
- 35 62. A method of inhibiting the transition of a hair

follicle from the anagen phase to the catagen phase comprising contacting the follicle with an effective amount of the pharmaceutical composition of claim 52.

5

63. The method of claim 56, wherein the cell is a keratinocyte.

10

64. The method of claim 57, wherein the cell is a keratinocyte.

65. The method of claim 58, wherein the cell is a keratinocyte.

15

66. The method of claim 59, wherein the cell is a keratinocyte.

67. The method of claim 57, wherein the subject is a human.

20

68. The method of claim 58, wherein the subject is a human.

25

69. The method of claim 60, wherein the subject is a human.

70. The method of claim 57, wherein the nucleic acid molecule is administered topically.

30

71. The method of claim 70, wherein the nucleic acid is administered dermally.

72. The method of claim 58, wherein the pharmaceutical composition is administered topically.

35

73. The method of claim 72, wherein the pharmaceutical composition is administered dermally.
74. The method of claim 60, wherein the pharmaceutical composition is administered topically.
75. The method of claim 74, wherein the pharmaceutical composition is administered dermally.
76. A method of producing the nucleic acid molecule of claim 43 comprising culturing a cell having therein a vector comprising a sequence encoding said nucleic acid molecule under conditions permitting the expression of the nucleic acid molecule by the cell.
77. A non-human transgenic mammal, wherein the mammal's genome:
- (a) has stably integrated therein a nucleotide sequence encoding a human Hairless Protein operably linked to a promoter, whereby the nucleotide sequence is expressed; and
 - (b) lacks an expressible endogenous Hairless Protein-encoding nucleic acid sequence.

1/6

FIGURE 1A

tctcccggga gccactcccc tgggagccctc tccagcccct gggctggaag caccagcaac	60
cctggggatg gggcagaccc tcacagcccg gggctctggag ccggtgtcgg agctcacatg	120
ggccccatgac ctctccagac atttggaaca atcaaggccc ttagaccagg gacagaccca	180
agcccaggcc ctcccagagg tcataggacg caaccctttg tgcccttggg ctatggaaga	240
ggtttgggaa cggctttggg gtggaagatg gccaaaggag cagcttgccc aggtgaggat	300
gaggcagggc agacacaggc cagtggggcg tgccatgtgc cacagatgga gaggaccagg	360
agccagtggc ccggcaggca cagcccgggt ggctggggcc agagcgccca tccctgaccc	420
gtgagaactc gactgcccc gccagctctg gcaactgccc ctcccagccg ccccgcccta	480
gcaccctggg gggcaccccc cccaaccgtg gcctgggtccg gccctcccg ccctttgctc	540
cagttcccgg gcttggcacc tatagtgggg gtgcgcgccg cctgccaggc tccggggccg	600
ggcccacggg aggggtgggc ggctgggaag ctggcacgct gcccggggg agcctctgtc	660
ggcaggcgcc cgggtgccgc gggggggagg gggaaacaaag ggctcattct ccccgtcgc	720
agccggtggc atcgccgggg cgttggcgga agccccggg gcccgggagg gggccggccc	780
aggcgcgcc gccgaatcac gggctcctgt ttcccgagg gtgctggagg aggaaaccgg	840
cggagcagct tccccactct cagttgcgcg tctggcgatg gcgatcagag gtcgtgctgc	900
gctctccgcc gcgctctacc tccattagcc gcgctgcgcg gtgctgcgcc ctgcgcggtg	960
cctctctcct gggctccagg atcgccccc accatccagg cagaccccc tccccggcc	1020
cctcgccctt tcccccaact cggccatctc cgaccgggg cgctgttcc ccccgccccg	1080
gcgcttctc tccctccggg ggcacccgct ccctagcccc gggccggccc tccccgggc	1140
gcagcacgga gtctcggcgt cccatggcgc aacctacggc ctcgcccag aagctggtgc	1200
ggccgatccg cgccgtgtgc cgcacctgc agatcccga gtccgacccc tccaacctgc	1260
ggccctagag cggccccgcc gcccggggg aaggagagcg cagcgcgct gagcagacag	1320
agcgggagaa cgcgtcctcg cccggcgcc gggaggcccc ggagctggcc catggggagc	1380
aggcgcccg tgccggccac gacgaccgcc accgcccgc cgcgaccgg ccggtgaagc	1440
ccagggaccc ccctctggga gagccccatg agggcaggag agtgatggag agtacccca	1500
gcttctgaa gggcacccca acctgggaga agacggcccc agagaacggc atcgtgagac	1560
aggagcccg cagccgcct cgagatggac tgcacatgg gccgctgtgc ctgggagagc	1620
ctgctccctt ttggaggggc gtcctgagca cccagactc ctggcttccc cctggcttcc	1680
cccaggcccc caaggacatg ctcccacttg tggagggcga gggccccag aatggggaga	1740
ggaaggtcaa ctggctgggc agcaaagg gactgcgctg gaaggaggcc atgcttacct	1800
atccgctggc attctgcggg ccagcgtgcc cacctcgtg tggccccctg atgcctgagc	1860
atagtgggtg ccattctcaag agtgaccctg tggccttccg gccctggcac tgccctttcc	1920

2/6

FIGURE 1B

ttctggagac caagatcctg gagcgagctc ccttctgggt gccacactgc ttgccaccct 1980
 acctagtgtc tggcctgccc ccagagcatc catgtgactg gccctgacc cgcacccct 2040
 ggggtatactc cgggggcccag cccaaagtgc cctctgcctt cagcttaggc agcaagggt 2100
 tttactacaa ggatccgagc attcccaggt tggcaaagga gcccttggca gctgcggaac 2160
 ctgggttgtt tggttaaac tctggtgggc acctgcagag agccggggag gccgaacgcc 2220
 cttcaactgca ccagagggat ggagagatgg gagctggccg gcagcagaat ccttgccgc 2280
 tcttctggg gcagccagac actgtgccct ggacctcctg gcccgcttgt cccccaggcc 2340
 ttgttcatac tottggaac gtctgggctg ggccaggcga tgggaacctt gggtagcagc 2400
 tggggccacc agcaacacca aggtgcccct ctctgagcc gcctgtcacc cagcggggct 2460
 gctgttcatac ctacccacc actaaagtg gggatcttg cccttgagg aagtgccag 2520
 agggcctgga ggggggtgcc agtgaggcca gcgaaccag cgaggaagt aacaaggcct 2580
 ctggccccag ggcctgtccc ccagccacc acaccaagct gaagaagaca tggctcacac 2640
 ggcactcgga gcagttttaa tgtccacgag gctgccctga ggtcgaggag aggcgggtg 2700
 ctcggtccg ggcctcaaa agggcaggca gcccagagt ccaggagca atgggcagtc 2760
 cagccccaa gcggccaccg gacctttcc caggcactgc agaacagggg gctgggggtt 2820
 ggcaggaggt gcgggacaca tcgataggga acaaggatgt ggactcggga cagcatgatg 2880
 agcagaaagg accccaagat ggcaggcca gtctccagga cccgggactt caggacatac 2940
 catgcctggc tctcctgca aaactggctc aatgccaaag ttgtgccag gcagctggag 3000
 agggaggag gacgcctgc cactctcagc aagtgcggag atcgctctg ggaggggagc 3060
 tgcagcagg ggaagacaca gccaccaact ccagctctga ggaaggccca ggtccggcc 3120
 ctgacagccg gctcagcaca ggcctcgcca agcacctgct cagtggttt ggggaccgac 3180
 tgtgccgcct gctgcggag gagcgggag ccctggctt gggcagcg gaaggccaag 3240
 ggcagccgt gacagaggac agcccaggca ttccacgctg ctgcagccgt tgccaccatg 3300
 gactcttcaa caccactgg cgatgtccc gctgcagcca ccggctgtgt gtggcctgtg 3360
 gtcgtgtggc aggcactgg cgggccagg agaaagcagg ctttcaggag cagtccgag 3420
 aggagtgcac gcaggaggcc ggcacgctg cctgttcct gatgctgacc cagtttgtct 3480
 ccagccaggc ttgagcag ctgagcactg caatgcacca ggtctgggtc aagtttgata 3540
 tccgggggca ctgccctgc caagctgatg ccgggtatg gggcccggt gatgcaggcc 3600
 agcagaagga atcaacacag aaacgcccc caactccaca accttctgc aatggcgaca 3660
 cccacaggac caagagcatc aaagaggaga ccccgattc cgctgagacc ccagcagag 3720
 accgtgctgg ccgagggccc ctgcctgtc cttctctct cgaactgctg gcttctaccg 3780
 cggtaaaact ctgcttggg catgagcgaa tacacatgg cttcgcccc gtcactccq 3840

3/6

FIGURE 1C

```

cctgcccag tgaigaccgc atcaccaaca tctggacag cattatcgca cagggtggtg 3900
aacggaagat ccaggagaaa gccctggggc cggggcttcg agctggcccg ggtctgcgca 3960
agggcctggg cctgcccctc tctccagtgc ggcccggct gcctcccoca ggggctttgc 4020
tgtggctgca ggagcccag ccttgccctc ggctggctt ccacctctc caggagcact 4080
ggaggcaggg ccagcctgtg ttggtgtcag ggatccaaag gacattgcag ggcaacctgt 4140
gggggacaga agctcttggg gcacttggag gccaggtgca ggctgtgagc cccctcggac 4200
ctcccagcc cagcagcctg ggagacaaa cattctggga gggcttctcc tggcctgagc 4260
ttcgccaaa gtcagacgag ggctctgtcc tctgtgtgca ccgagctttg ggggatgagg 4320
acaccagcag ggtggagaac ctactgtcca gtctgccact tccgagtagc tgcgccctcc 4380
atggaaaact caacctggct tctacctcc caccgggct tgccttgcgt cactggagc 4440
cccagctctg ggcagcctat ggtgtgagcc cgcaccggg acacctggg accaagaacc 4500
tctgtgtgga ggtggccgac ctggtcagca tctgtgtgca tgccgacaca cactgcctg 4560
cctggcaccg ggcacagaaa gacttccttt caggcctgga cggggagggg ctctgtgtc 4620
cgggcagcca ggtcagcact gtgtggcacg tgttcgggg acaggacgcc cagcgcatcc 4680
gccgctttct ccagatggtg tgcccggccg gggcaggcgc cctggagcct ggcgcccag 4740
gcagctgcta cctggatgca gggctgcggc ggccctgcg ggaggagtgg ggctgtgagc 4800
gctggacct gctccaggcc cccggagagg ccgtgtgtgt gcctgcaggg gctccccagc 4860
aggtgcaggg cctggtgagc acagttagc tcaactagca ctctctctcc cctgagacct 4920
ctgccctctc tgctcagctc tgccaccagg gaccagcct tccccctgac tgccacctgc 4980
tttatgcccc gatggactgg gctgtgttcc aagcagtga ggtggccgtg gggacattac 5040
aggaggccaa atagagggat gctaggtgtc tgggatcggg gtggggacag gtagaccag 5100
tgctcagcdc aggcacaact tcagcagggg atggcgctag gggacttggg gatttctgt 5160
caacccccaca agcaccactc tgggcacaag cagggcactc tgttcccctc ccccttaagc 5220
caacaaccac agtgccacca agtcacacc tgccttctc aggtggcat ctccccacc 5280
ctgtgcccct tttcatgta ccaggcccgc actgggggca attgacttcc tccaatcccc 5340
actcctccga gaccaggag acaaacagcc ctctcttggg gaaacttggg aatcattctg 5400
gcttaaaaaa cacctctctc tgctgtcac tccgctgag cccactctac tgcccagct 5460
ccgtttctac caccgcatcc tactgggct cactgcaggc atgtgaaca aggggcctcc 5520
aaccttctgc cctcctgcca aaagatctgg ggagtgtgag gagagggtgg catcaggagc 5580
tgctcaggct tggcgagggg agcggcatgg gcgatgtcac tcatgccctt cccggtcgc 5640
ccgcttcct cctcatgat ttccattaaa gtctgtgtt ttgaaaaaa aaaaaaaaaa 5700
aaaaaaaaa 5709

```


4/6

FIGURE 2B



FIGURE 2D



FIGURE 2A




FIGURE 2C




5/6

FIGURE 3



6/6

FIGURE 4



SEQUENCE LISTING

<110> THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK ET AL

<120> NUCLEIC ACIDS FOR INHIBITING HAIRLESS PROTEIN EXPRESSION AND METHODS OF USE THEREOF

<130> 0575/62637-A-PCT

<160> 27

<170> PatentIn version 3.0

<210> 1

<211> 5709

<212> DNA

<213> Homo sapiens

<400> 1

```

tctcccggga gccactcccc tgggcgcctc tccagcccct gggctggaag caccagcaac      60
cctggggatg gggcagaccc tcacagcccg gggctctggag ccggtgtcgg agctcacatg     120
ggcccatgac ctctccagac atttgcaaaa atcaaggccc ttagaccagg gacagaccca     180
agcccaggcc ctcccagagg tcataggacg caaccctttg tgcccttggg ctatggaaga     240
ggtttgggaa cggttttggg gtggaagatg gccaaaggag cagcttggcc aggtgaggat     300
gaggcagggc agacacaggc cagtggggcg tgccatgtgc cacagatgga gaggaccagg     360
agccagtggc ccggcaggca cagcccgggt ggcggtgggc agagcgccca tctactgacc     420
gtgagaactc gactgcccct gccagctctg gcactgcccc ctcccagccg ccccgcccta     480
gcaccctggg gggcaccctg cccaaccgtg gcctgggtccg gcccctcccg ccctttgctc     540
cagttcccgg gcttggcacc tatagtgggg gtgcccgcgg cctgccaggc tccggggccg     600
ggcccacggg aggggtgggg ggctgggaag ctggcacgct gccccggggg agcctctgtc     660
ggcaggcgcc cgggtgccgc gggggggagg gggaacaaag ggctcattct ccccggtcgc     720
agccggtggc atcgccgggg cgttggcgga agccccggg gcccgggagg gggccggccc     780
aggcgcggcc gccgaatcac gggctcctgt ttcccgagg gtgctggagg aggaaaccgg     840
cggagcagct tccccactct cagttgcgcg tctggcgatg gcgatcagag gtcgtgctgc     900
gctctccgcc gcgtctacc tccattagcc gcgctgcgcg gtgctgccc ctcgccggtg     960
cctctctcct ggggtcccagg atcggcccc accatccagg cacgaccccc ttccccggcc    1020
cctcggcctt tccccaaact cggccatctc cgacccgggg cgcgtgttcc ccccgccccg    1080
gcgccttctc tccctccggg ggcacccgct ccctagcccc ggcccggccc tccccggggc    1140
gcagcacgga gtctcggcgt cccatggcgc aacctacggc ctcgcccag aagctggtgc    1200

```

ggccgatccg cgccgtgtgc cgcacccctgc agatcccggg gtccgacccc tocaacctgc 1260
ggccctagag cgcccccgcc gccccggggg aaggagagcg cgagcgcgct gagcagacag 1320
agcgggagaa cgcgctcctcg cccgcccggc gggaggcccc ggagctggcc catggggagc 1380
aggcggcccg tgccggccac gacgaccgcc accgcccgcg ccgcgaccgg ccggtgaagc 1440
ccagggaccc ccctctggga gagccccatg agggcaggag agtgatggag agtacgcca 1500
gcttctgaa gggcacccca acctgggaga agacggcccc agagaacggc atcgtgagac 1560
aggagcccgg cagcccgct cgagatggac tgcacatgg gccgctgtgc ctgggagagc 1620
ctgctccctt ttggaggggc gtcctgagca cccagactc ctggcttccc cctggcttcc 1680
cccagggccc caaggacatg ctcccacttg tggagggcga gggccccag aatggggaga 1740
ggaaggtcaa ctggctgggc agcaaagg gactgcgctg gaaggaggcc atgcttacc 1800
atccgctggc attctgcggg ccagcgtgcc cacctcgtg tggccccctg atgcctgagc 1860
atagtgggtg ccatctcaag agtgaccctg tggccttcg gccctggcac tgcccttcc 1920
ttctggagac caagatcctg gagcgagctc ccttctgggt gccacactgc ttgccacct 1980
acctagtgtc tggcctgccc ccagagcatc catgtgactg gccctgacc ccgcacctc 2040
gggtatactc cggggggccag cccaaagtgc cctctgcctt cagcttaggc agcaagggt 2100
tttactacaa ggatccgagc attcccaggt tggcaaagga gcccttggca gctgcggaac 2160
ctgggttgtt tggcttaaac tctggtgggc acctgcagag agccggggag gccgaacgcc 2220
cttcaactgca ccagagggat ggagagatgg gagctggccg gcagcagaat ccttgcccg 2280
tcttctggg gcagccagac actgtgcctt ggacctcctg gcccgcttgt ccccaggcc 2340
ttgttcatac tcttggaac gtctgggctg ggccaggcga tgggaacctt gggtagcagc 2400
tggggccacc agcaacacca aggtgcccc ctctgagcc gcctgtcacc cagcggggct 2460
gctgttcac ctacccaccc actaaagggt gggatcttgg cccttggtgg aagtgccagg 2520
agggcctgga ggggggtgcc agtgaggcca gcgaaccag cgaggaagtg aacaaggcct 2580
ctggccccag ggcctgtccc ccagccacc acaccaagt gaagaagaca tggctcacac 2640
ggcactcgga gcagtttgaa tgtccacgcg gctgccctga ggtcgaggag aggccggtt 2700
ctcggtccg ggccctcaaa agggcaggca gccccagggt ccaggagca atgggcagtc 2760
cagccccaa gcggccaccg gacccttcc caggcactgc agaacagggg gctgggggtt 2820
ggcaggaggt gcgggacaca tcgatagga acaaggatgt ggactcggga cagcatgatg 2880
agcagaaagg accccaagat ggccaggcca gtctccagga cccgggactt caggacatac 2940
catgcctggc tctccctgca aaactggctc aatgccaaag ttgtgcccag gcagctggag 3000

aggaggagg gcacgcctgc cactctcagc aagtgcggag atcgccctctg ggaggggagc 3060
tgcagcagga ggaagacaca gccaccaact ccagctctga ggaaggcca ggggccggcc 3120
ctgacagccg gctcagcaca ggcctcgcca agcacctgct cagtggtttg ggggaccgac 3180
tgtgccgcct gctcggagg gagcgggagg ccctggcttg ggccagcgg gaaggccaag 3240
ggccagccgt gacagaggac agcccaggca ttccacgctg ctgcagccgt tgccaccatg 3300
gactcttcaa ccccactgg cgatgtcccc gctgcagcca ccggctgtgt gtggcctgtg 3360
gtcgtgtggc aggcactggg cgggccaggg agaaagcagg ctttcaggag cagtccgagg 3420
aggagtgcac gcaggaggcc gggcacgctg cctgttcctt gatgctgacc cagtttgtct 3480
ccagccaggc tttggcagag ctgagcactg caatgcacca ggtctgggtc aagtttgata 3540
tccgggggca ctgcccctgc caagctgatg cccgggtatg gggcccgagg gatgcaggcc 3600
agcagaagga atcaacacag aaaacgcccc caactccaca accttctgc aatggcgaca 3660
cccacaggac caagagcatc aaagaggaga cccccgattc cgctgagacc ccagcagagg 3720
accgtgctgg ccgaggggcc ctgccttgtc cttctctctg cgaactgctg gcttctaccg 3780
cgggtcaaact ctgcttgggc catgagcgaa tacacatggc cttcgcccc gtcactccgg 3840
ccctgcccag tgatgaccgc atcaccaaca tcctggacag cattatcgca cagggtgtgg 3900
aacggaagat ccaggagaaa gccctggggc cggggcttcg agctggcccg ggtctgcgca 3960
agggcctggg cctgcccctc tctccagtgc gggcccggtt gctcccca ggggctttgc 4020
tgtggctgca ggagccccag ccttgccctc ggcgtggctt ccacctcttc caggagcact 4080
ggaggcaggg ccagcctgtg ttggtgtcag ggatccaaag gacattgcag ggcaacctgt 4140
gggggacaga agctcttggg gacttggag gccagggtgca ggcgctgagc cccctcggac 4200
ctccccagcc cagcagcctg ggcagcacia cattctggga gggcttctcc tggcctgagc 4260
ttcgccaaa gtcagacgag ggctctgtcc tcctgctgca ccgagctttg ggggatgagg 4320
acaccagcag ggtggagaac ctagctgcca gtctgccact tccggagtac tgcgccctcc 4380
atgaaaaact caacctggct tcctacctcc caccgggcct tgccctgcgt ccactggagc 4440
cccagctctg ggcagcctat ggtgtgagcc cgcaccgggg acacctgggg accaagaacc 4500
tctgtgtgga ggtggccgac ctggtcagca tcctggtgca tgccgacaca ccactgcctg 4560
cctggcaccg ggcacagaaa gacttccttt caggcctgga cggggagggg ctctggtctc 4620
cgggcagcca ggtcagcact gtgtggcacg tgttccgggc acaggacgcc cagcgcatcc 4680
gccgctttct ccagatggtg tgcccggccg gggcaggcgc cctggagcct ggcgccccag 4740

```

gcagctgcta cctggatgca gggctgcggc ggcgcctgcg ggaggagtgg ggcgtgagct 4800
gctggaccct gctccaggcc cccggagagg ccgtgctggt gcctgcaggg gctccccacc 4860
agggtcaggg cctggtgagc acagtcagcg tcactcagca cttcctctcc cctgagacct 4920
ctgcccctctc tgctcagctc tgccaccagg gaccagacct tccccctgac tgccacctgc 4980
tttatgccca gatggactgg gctgtgttcc aagcagtga ggtggccgtg gggacattac 5040
aggaggccaa atagagggat gctaggtgtc tgggatcggg gtggggacag gtagaccagg 5100
tgctcagccc aggcacaact tcagcagggg atggcgctag gggacttggg gatttctggt 5160
caaccccaca agcaccactc tgggcacaag cagggcactc tgttcccctc ccccttaagc 5220
caacaaccac agtgccacca agtcacacc tgtccttctc aggttggcat cccccacc 5280
ctgtgcccct tttcatggta ccaggcccg cactggggca attgacttcc tccaatcccc 5340
actcctccga gaccaggag acaaacagcc cttccttggg gaaacttggg aatcattctg 5400
gcttaaacia cacctctcc tgctgtcac tccgctgag cccactctac tgcccagct 5460
ccgtttctac caccgatcc tcactgggct cactgcaggc atgctgaaca aggggcctcc 5520
aaccttctgc cctctgcca aaagatctgg ggagtgtgag gagagggtgg catcaggagc 5580
tgctcaggct tggcggaggg agcggcatgg gcgatgtcac tcatgccctt cccggtccgc 5640
ccgcttccct ccttcatgat ttccattaaa gtctgttgtt ttgaaaaaaaa aaaaaaaaaa 5700
aaaaaaaaa 5709

```

```

<210> 2
<211> 29
<212> DNA
<213> Artificial/Unknown

```

```

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

```

```

<400> 2
cccatggggc tagctacaac gagcagtc

```

29

```

<210> 3
<211> 29
<212> DNA
<213> Artificial/Unknown

```

```

<220>
<221> misc_feature
<222> ()..()
<223> deoxy ribozyme

```

<400> 3
cggccccaggc tagctacaac gaggtgcag 29

<210> 4
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy ribozyme

<400> 4
ctcaggaggc tagctacaac gagcccctc 29

<210> 5
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

<400> 5
gggagcaggc tagctacaac gagtccttg 29

<210> 6
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

<400> 6
ctccccaggc tagctacaac gatctgggg 29

<210> 7
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()

<223> deoxy - ribozyme

<400> 7
cagccagggc tagctacaac gatgacctt

29

<210> 8
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

<400> 8
cagcggaggc tagctacaac gagggtaag

29

<210> 9
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

<400> 9
cgcagaaggc tagctacaac gagccagcg

29

<210> 10
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

<400> 10
tgcggggggc tagctacaac gacaggggc

29

<210> 11
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature

<222> ()..()
<223> deoxy - ribozyme

<400> 11
aggggtgggc tagctacaac gaggggtca

29

<210> 12
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

<400> 12
cccggagggc tagctacaac gaataccca

29

<210> 13
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

<400> 13
gcctaagggc tagctacaac gatgaaggc

29

<210> 14
<211> 30
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> deoxy - ribozyme

<400> 14
ggcaaggagg ctagctacaa cgatctgctg

30

<210> 15
<211> 29
<212> DNA
<213> Artificial/Unknown

<220>

<221> misc_feature
 <222> ()..()
 <223> deoxy - ribozyme

<400> 15
 gttcccaggc tagctacaac gacgcctgg

29

<210> 16
 <211> 29
 <212> DNA
 <213> Artificial/Unknown

<220>
 <221> misc_feature
 <222> ()..()
 <223> deoxy - ribozyme

<400> 16
 cagctggggc tagctacaac gaacccaag

29

<210> 17
 <211> 1189
 <212> PRT
 <213> Homo sapiens

<400> 17

Met	Glu	Ser	Thr	Pro	Ser	Phe	Leu	Lys	Gly	Thr	Pro	Thr	Trp	Glu	Lys
1				5					10					15	
Thr	Ala	Pro	Glu	Asn	Gly	Ile	Val	Arg	Gln	Glu	Pro	Gly	Ser	Pro	Pro
			20					25					30		
Arg	Asp	Gly	Leu	His	His	Gly	Pro	Leu	Cys	Leu	Gly	Glu	Pro	Ala	Pro
		35					40					45			
Phe	Trp	Arg	Gly	Val	Leu	Ser	Thr	Pro	Asp	Ser	Trp	Leu	Pro	Pro	Gly
	50					55					60				
Phe	Pro	Gln	Gly	Pro	Lys	Asp	Met	Leu	Pro	Leu	Val	Glu	Gly	Glu	Gly
65					70					75					80
Pro	Gln	Asn	Gly	Glu	Arg	Lys	Val	Asn	Trp	Leu	Gly	Ser	Lys	Glu	Gly
			85						90					95	
Leu	Arg	Trp	Lys	Glu	Ala	Met	Leu	Thr	His	Pro	Leu	Ala	Phe	Cys	Gly
			100					105						110	
Pro	Ala	Cys	Pro	Pro	Arg	Cys	Gly	Pro	Leu	Met	Pro	Glu	His	Ser	Gly
		115					120					125			
Gly	His	Leu	Lys	Ser	Asp	Pro	Val	Ala	Phe	Arg	Pro	Trp	His	Cys	Pro
	130					135					140				
Phe	Leu	Leu	Glu	Thr	Lys	Ile	Leu	Glu	Arg	Ala	Pro	Phe	Trp	Val	Pro

145		150		155		160
Thr Cys Leu Pro	Pro Tyr Leu Val	Ser Gly Leu Pro	Pro Pro Glu His	Pro		
	165	170	175			
Cys Asp Trp Pro	Leu Thr Pro His	Pro Trp Val Tyr	Ser Gly Gly Gln			
	180	185	190			
Pro Lys Val Pro	Ser Ala Phe Ser	Leu Gly Ser Lys	Gly Phe Tyr Tyr			
	195	200	205			
Lys Asp Pro Ser	Ile Pro Arg Leu	Ala Lys Glu Pro	Leu Ala Ala Ala			
	210	215	220			
Glu Pro Gly Leu	Phe Gly Leu Asn	Ser Gly Gly His	Leu Gln Arg Ala			
	225	230	235	240		
Gly Glu Ala Glu	Arg Pro Ser Leu	His Gln Arg Asp	Gly Glu Met Gly			
	245	250	255			
Ala Gly Arg Gln	Gln Asn Pro Cys	Pro Leu Phe Leu	Gly Gln Pro Asp			
	260	265	270			
Thr Val Pro Trp	Thr Ser Trp Pro	Ala Cys Pro Pro	Gly Leu Val His			
	275	280	285			
Thr Leu Gly Asn	Val Trp Ala Gly	Pro Gly Asp Gly	Asn Leu Gly Tyr			
	290	295	300			
Gln Leu Gly Pro	Pro Ala Thr Pro	Arg Cys Pro Ser	Pro Glu Pro Pro			
	305	310	315	320		
Val Thr Gln Arg	Gly Cys Cys Ser	Ser Tyr Pro Pro	Thr Lys Gly Gly			
	325	330	335			
Asp Leu Gly Pro	Cys Gly Lys Cys	Gln Glu Gly Leu	Glu Gly Gly Ala			
	340	345	350			
Ser Gly Ala Ser	Glu Pro Ser Glu	Glu Val Asn Lys	Ala Ser Gly Pro			
	355	360	365			
Arg Ala Cys Pro	Pro Ser His His	Thr Lys Leu Lys	Lys Thr Trp Leu			
	370	375	380			
Thr Arg His Ser	Glu Gln Phe Glu	Cys Pro Arg Gly	Cys Pro Glu Val			
	385	390	395	400		
Glu Glu Arg Pro	Val Ala Arg Leu	Arg Ala Leu Lys	Arg Ala Gly Ser			
	405	410	415			
Pro Glu Val Gln	Gly Ala Met Gly	Ser Pro Ala Pro	Lys Arg Pro Pro			
	420	425	430			
Asp Pro Phe Pro	Gly Thr Ala Glu	Gln Gly Ala Gly	Gly Leu Gln Glu			
	435	440	445			
Val Arg Asp Thr	Ser Ile Gly Asn	Lys Asp Val Asp	Ser Gly Gln His			
	450	455	460			

Asp Glu Gln Lys Gly Pro Gln Asp Gly Gln Ala Ser Leu Gln Asp Pro
 465 470 475 480
 Gly Leu Gln Asp Ile Pro Cys Leu Ala Leu Pro Ala Lys Leu Ala Gln
 485 490 495
 Cys Gln Ser Cys Ala Gln Ala Ala Gly Glu Gly Gly Gly His Ala Cys
 500 505 510
 His Ser Gln Gln Val Arg Arg Ser Pro Leu Gly Gly Glu Leu Gln Gln
 515 520 525
 Glu Glu Asp Thr Ala Thr Asn Ser Ser Ser Glu Glu Gly Pro Gly Ser
 530 535 540
 Gly Pro Asp Ser Arg Leu Ser Thr Gly Leu Ala Lys His Leu Leu Ser
 545 550 555 560
 Gly Leu Gly Asp Arg Leu Cys Arg Leu Leu Arg Arg Glu Arg Glu Ala
 565 570 575
 Leu Ala Trp Ala Gln Arg Glu Ser Gln Gly Pro Ala Val Thr Glu Asp
 580 585 590
 Ser Pro Gly Ile Pro Arg Cys Cys Ser Arg Cys His His Gly Leu Phe
 595 600 605
 Asn Thr His Trp Arg Cys Pro Arg Cys Ser His Arg Leu Cys Val Ala
 610 615 620
 Cys Gly Arg Val Ala Gly Thr Gly Arg Ala Arg Glu Lys Ala Gly Phe
 625 630 635 640
 Gln Glu Gln Ser Ala Glu Glu Cys Thr Gln Glu Ala Gly His Ala Ala
 645 650 655
 Cys Ser Leu Met Leu Thr Gln Phe Val Ser Ser Gln Ala Leu Ala Glu
 660 665 670
 Leu Ser Thr Ala Met His Gln Val Trp Val Lys Phe Asp Ile Arg Gly
 675 680 685
 His Cys Pro Cys Gln Ala Asp Ala Arg Val Trp Ala Pro Gly Asp Ala
 690 695 700
 Gly Gln Gln Lys Glu Ser Thr Gln Lys Thr Pro Pro Thr Pro Gln Pro
 705 710 715 720
 Ser Cys Asn Gly Asp Thr His Arg Thr Lys Ser Ile Lys Glu Glu Thr
 725 730 735
 Pro Asp Ser Ala Glu Thr Pro Ala Glu Asp Arg Ala Gly Arg Gly Pro
 740 745 750
 Leu Pro Cys Pro Ser Leu Cys Glu Leu Leu Ala Ser Thr Ala Val Lys
 755 760 765
 Leu Cys Leu Gly His Glu Arg Ile His Met Ala Phe Ala Pro Val Thr
 770 775 780

Pro Ala Leu Pro Ser Asp Asp Arg Ile Thr Asn Ile Leu Asp Ser Ile
 785 790 795 800
 Ile Ala Gln Val Val Glu Arg Lys Ile Gln Glu Lys Ala Leu Gly Pro
 805 810 815
 Gly Leu Arg Ala Gly Pro Gly Leu Arg Lys Gly Leu Gly Leu Pro Leu
 820 825 830
 Ser Pro Val Arg Pro Arg Leu Pro Pro Gly Ala Leu Leu Trp Leu
 835 840 845
 Gln Glu Pro Gln Pro Cys Pro Arg Arg Gly Phe His Leu Phe Gln Glu
 850 855 860
 His Trp Arg Gln Gly Gln Pro Val Leu Val Ser Gly Ile Gln Arg Thr
 865 870 875 880
 Leu Gln Gly Asn Leu Trp Gly Thr Glu Ala Leu Gly Ala Leu Gly Gly
 885 890 895
 Gln Val Gln Ala Leu Ser Pro Leu Gly Pro Pro Gln Pro Ser Ser Leu
 900 905 910
 Gly Ser Thr Thr Phe Trp Glu Gly Phe Ser Trp Pro Glu Leu Arg Pro
 915 920 925
 Lys Ser Asp Glu Gly Ser Val Leu Leu Leu His Arg Ala Leu Gly Asp
 930 935 940
 Glu Asp Thr Ser Arg Val Glu Asn Leu Ala Ala Ser Leu Pro Leu Pro
 945 950 955 960
 Glu Tyr Cys Ala Leu His Gly Lys Leu Asn Leu Ala Ser Tyr Leu Pro
 965 970 975
 Pro Gly Leu Ala Leu Arg Pro Leu Glu Pro Gln Leu Trp Ala Ala Tyr
 980 985 990
 Gly Val Ser Pro His Arg Gly His Leu Gly Thr Lys Asn Leu Cys Val
 995 1000 1005
 Glu Val Ala Asp Leu Val Ser Ile Leu Val His Ala Asp Thr Pro
 1010 1015 1020
 Leu Pro Ala Trp His Arg Ala Gln Lys Asp Phe Leu Ser Gly Leu
 1025 1030 1035
 Asp Gly Glu Gly Leu Trp Ser Pro Gly Ser Gln Val Ser Thr Val
 1040 1045 1050
 Trp His Val Phe Arg Ala Gln Asp Ala Gln Arg Ile Arg Arg Phe
 1055 1060 1065
 Leu Gln Met Val Cys Pro Ala Gly Ala Gly Ala Leu Glu Pro Gly
 1070 1075 1080
 Ala Pro Gly Ser Cys Tyr Leu Asp Ala Gly Leu Arg Arg Arg Leu

1085	1090	1095
Arg Glu Glu Trp Gly Val 1100	Ser Cys Trp Thr Leu 1105	Leu Leu Gln Ala Pro 1110
Gly Glu Ala Val Leu Val 1115	Pro Ala Gly Ala Pro 1120	His Gln Val Gln 1125
Gly Leu Val Ser Thr Val 1130	Ser Val Thr Gln His 1135	Phe Leu Ser Pro 1140
Glu Thr Ser Ala Leu Ser 1145	Ala Gln Leu Cys His 1150	Gln Gly Pro Ser 1155
Leu Pro Pro Asp Cys His 1160	Leu Leu Tyr Ala Gln 1165	Met Asp Trp Ala 1170
Val Phe Gln Ala Val Lys 1175	Val Ala Val Gly Thr 1180	Leu Gln Glu Ala 1185

Lys

<210> 18
 <211> 15
 <212> DNA
 <213> Artificial/Unknown

<220>
 <221> misc_feature
 <222> ()..()
 <223> Catalytic domain

<400> 18
 ggctagctac aacga

15

<210> 19
 <211> 25
 <212> DNA
 <213> Artificial/Unknown

<220>
 <221> misc_feature
 <222> ()..()
 <223> Catalytic domain

<400> 19
 ctgatgagtc cgtgaggacg aaaca

25

<210> 20
 <211> 56
 <212> DNA
 <213> Artificial/Unknown

<220>

<221> misc_feature
<222> ()..()
<223> Ribozyme

<400> 20
cggccggcgg gcgagctgat gagtccgtga ggacgaaaca cgcgttctcc cgctct 56

<210> 21
<211> 58
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> Ribozyme

<400> 21
gagtctgggg tgctcagctg atgagtcctg gaggacgaaa cacgcccctc caaaaagg 58

<210> 22
<211> 58
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> Ribozyme

<400> 22
ttgtgcacca gccagttctg atgagtcctg gaggacgaaa caccttcctc tccccatt 58

<210> 23
<211> 58
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> Ribozyme

<400> 23
gctctggggg caggccactg atgagtcctg gaggacgaaa cacactaggt aggggtggc 58

<210> 24
<211> 58
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> Ribozyme

<400> 24
atgaacaagg cctggggctg atgagtcctg gaggacgaaa cacaagcggg ccaggagg 58

<210> 25
<211> 58
<212> DNA
<213> Artificial/Unknown

<220>
<221> misc_feature
<222> ()..()
<223> Ribozyme

<400> 25
tcgcctggcc cagcccactg atgagtcctg gaggacgaaa cacgttgcca agagtatg 58

<210> 26
<211> 18
<212> DNA
<213> ARTIFICIALSEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> ANTISENSEOLIGONUCLEOTIDEDIRECTED AT HUMAN HAIRLESS

<400> 26
gctgggcata ctctccat 18

<210> 27
<211> 18
<212> DNA
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> ANTISENSE OLIGONUCLEOTIDE DIRECTED AT HUMAN HAIRLESS

<400> 27
catcactctc ctgccctc 18